Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Start Date
3/25/2026
Completion Date
10/1/2027
Summary
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.
Detailed Description
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, multicenter study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of LB-102 100 mg once daily (QD) and LB-102 50 mg QD versus placebo QD for the treatment of adult patients with an acute exacerbation of schizophrenia
Eligibility Criteria
Age Range: 18 years to 65 years
Interventions
LB-102 (50 mg tablet)
LB-102 (100 mg tablet)
Placebo
Conditions
Locations
Pillar Clinical Research
Bentonville, Arkansas 72712
United States
Pillar Clinical Research
Little Rock, Arkansas 72204
United States
Woodland International Research Group
Little Rock, Arkansas 72211
United States
ProScience Research Group
Culver City, California 90230
United States
CenExel
Garden Grove, California 92845
United States
Synergy San Diego
Lemon Grove, California 92064
United States
Clinical Innovations, Inc.
Riverside, California 92506
United States
Health Synergy Clinical Research
Boynton Beach, Florida 33426
United States
Innovative Clinical Research
Miami Lakes, Florida 33016
United States
Accelerated Clinical Trial
Snellville, Georgia 30078
United States
Pillar Clinical Research
Chicago, Illinois 60641
United States
Arch Clinical Trials
St Louis, Missouri 63141
United States
Neuro-Behavioral Clinical Research
North Canton, Ohio 44720
United States